Preliminary results from a Phase 1 study assessing Atara Biotherapeutics’ (NASDAQ:ATRA) ATA188 in patients with progressive multiple sclerosis (MS) demonstrated an encouraging safety profile. The data were presented at the European Academy of Neurology Annual Congress in Oslo.
Results from the first three dose cohorts showed no dose-limiting toxicities and no serious treatment-emergent adverse events.
The study is ongoing. The primary objective is to identify the optimal dose for a Phase 2 trial.
ATA188 is an allogeneic Epstein-Barr virus (EBV) cytotoxic T lymphocyte (CTL) immunotherapy that targets EBV antigens that the company believes play a key role in the treatment of MS.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.